These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria. Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729 [TBL] [Abstract][Full Text] [Related]
5. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool. Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634 [TBL] [Abstract][Full Text] [Related]
6. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone. Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435 [TBL] [Abstract][Full Text] [Related]
7. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria. Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884 [TBL] [Abstract][Full Text] [Related]
8. NTBC and alkaptonuria. Anikster Y; Nyhan WL; Gahl WA Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357 [No Abstract] [Full Text] [Related]
9. Use of nitisinone in patients with alkaptonuria. Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605 [TBL] [Abstract][Full Text] [Related]
10. The role of nitisinone in tyrosine pathway disorders. Lock E; Ranganath LR; Timmis O Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991 [TBL] [Abstract][Full Text] [Related]
11. A father's fight to help his sons - and fix clinical trials. Adam D Nature; 2019 Jan; 565(7738):148-151. PubMed ID: 30626961 [No Abstract] [Full Text] [Related]
12. Evaluating the aortic stenosis phenotype before and after the effect of homogentisic acid lowering therapy: Analysis of a large cohort of eighty-one alkaptonuria patients. Ranganath LR; Heseltine T; Khedr M; Fisher MF Mol Genet Metab; 2021 Jul; 133(3):324-331. PubMed ID: 34059444 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600 [TBL] [Abstract][Full Text] [Related]
14. Natural history of alkaptonuria. Phornphutkul C; Introne WJ; Perry MB; Bernardini I; Murphey MD; Fitzpatrick DL; Anderson PD; Huizing M; Anikster Y; Gerber LH; Gahl WA N Engl J Med; 2002 Dec; 347(26):2111-21. PubMed ID: 12501223 [TBL] [Abstract][Full Text] [Related]
15. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Introne WJ; Perry MB; Troendle J; Tsilou E; Kayser MA; Suwannarat P; O'Brien KE; Bryant J; Sachdev V; Reynolds JC; Moylan E; Bernardini I; Gahl WA Mol Genet Metab; 2011 Aug; 103(4):307-14. PubMed ID: 21620748 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria. Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423 [TBL] [Abstract][Full Text] [Related]
18. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116 [TBL] [Abstract][Full Text] [Related]
19. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria. Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR J Inherit Metab Dis; 2024 Jul; 47(4):664-673. PubMed ID: 38487984 [TBL] [Abstract][Full Text] [Related]
20. Preventive use of nitisinone in alkaptonuria. Wolffenbuttel BHR; Heiner-Fokkema MR; van Spronsen FJ Orphanet J Rare Dis; 2021 Aug; 16(1):343. PubMed ID: 34344451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]